Conor E Steuer1, Madhusmita Behera1, Lynne Berry2, Sungjin Kim3, Michael Rossi1, Gabriel Sica1, Taofeek K Owonikoko1, Bruce E Johnson4, Mark G Kris5, Paul A Bunn6, Fadlo R Khuri1, Edward B Garon7, Suresh S Ramalingam1. 1. Winship Cancer Institute, Emory University, Atlanta, Georgia. 2. Vanderbilt University School of Medicine, Nashville, Tennessee. 3. Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California. 4. Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Memorial Sloan Kettering Cancer Center, New York, New York. 6. University of Colorado Cancer Center, Aurora, Colorado. 7. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities has been understudied. The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population. METHODS: Patients with metastatic lung adenocarcinomas from 14 US sites were enrolled in the LCMC1. Tumor samples were collected from 2009 through 2012 with multiplex genotyping performed on 10 oncogenic drivers (KRAS, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase (ALK) rearrangements, ERBB2 [formerly human epidermal growth factor receptor 2], BRAF, PIK3CA, MET amplification, NRAS, MEK1, and AKT1). Patients were classified as white, Asian, African American (AA), or Latino. The driver mutation frequency, the treatments, and the survival from diagnosis were determined. RESULTS: One thousand seven patients were included. Whites represented the majority (n = 838); there were 60 AAs, 48 Asians, and 28 Latinos. Asian patients had the highest rate of oncogenic drivers with 81% (n = 39), and they were followed by Latinos with 68% (n = 19), whites with 61% (n = 511), and AAs with 53% (n = 32). For AAs, the EGFR mutation frequency was 22%, the KRAS frequency was 17%, and the ALK frequency was 4%. Asian patients were most likely to receive targeted therapies (51% vs 27% for AAs). There were no significant differences in overall survival. CONCLUSIONS: Differences were observed in the prevalence of oncogenic drivers in lung adenocarcinomas and in subsequent treatments among racial groups. The lowest frequency of drivers was seen for AA patients; however, more than half of AA patients had a driver, and those treated with targeted therapy had outcomes similar to those of other races. Cancer 2016;122:766-772.
BACKGROUND: The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities has been understudied. The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population. METHODS:Patients with metastatic lung adenocarcinomas from 14 US sites were enrolled in the LCMC1. Tumor samples were collected from 2009 through 2012 with multiplex genotyping performed on 10 oncogenic drivers (KRAS, epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase (ALK) rearrangements, ERBB2 [formerly humanepidermal growth factor receptor 2], BRAF, PIK3CA, MET amplification, NRAS, MEK1, and AKT1). Patients were classified as white, Asian, African American (AA), or Latino. The driver mutation frequency, the treatments, and the survival from diagnosis were determined. RESULTS: One thousand seven patients were included. Whites represented the majority (n = 838); there were 60 AAs, 48 Asians, and 28 Latinos. Asian patients had the highest rate of oncogenic drivers with 81% (n = 39), and they were followed by Latinos with 68% (n = 19), whites with 61% (n = 511), and AAs with 53% (n = 32). For AAs, the EGFR mutation frequency was 22%, the KRAS frequency was 17%, and the ALK frequency was 4%. Asian patients were most likely to receive targeted therapies (51% vs 27% for AAs). There were no significant differences in overall survival. CONCLUSIONS: Differences were observed in the prevalence of oncogenic drivers in lung adenocarcinomas and in subsequent treatments among racial groups. The lowest frequency of drivers was seen for AA patients; however, more than half of AA patients had a driver, and those treated with targeted therapy had outcomes similar to those of other races. Cancer 2016;122:766-772.
Authors: Oscar Arrieta; Andrés Felipe Cardona; Guillermo Federico Bramuglia; Aly Gallo; Alma D Campos-Parra; Silvia Serrano; Marcelo Castro; Alejandro Avilés; Edgar Amorin; Ricardo Kirchuk; Mauricio Cuello; José Borbolla; Omar Riemersma; Henry Becerra; Rafael Rosell Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Oscar Arrieta; Andrés F Cardona; Claudio Martín; Luis Más-López; Luis Corrales-Rodríguez; Guillermo Bramuglia; Omar Castillo-Fernandez; Matthew Meyerson; Eduardo Amieva-Rivera; Alma Delia Campos-Parra; Hernán Carranza; Juan Carlos Gómez de la Torre; Yanina Powazniak; Fernando Aldaco-Sarvide; Carlos Vargas; Mariana Trigo; Manuel Magallanes-Maciel; Jorge Otero; Roberto Sánchez-Reyes; Mauricio Cuello Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Norihiro Yamaguchi; Paul A Vanderlaan; Erik Folch; David H Boucher; Hannah M Canepa; Michael S Kent; Sidharta P Gangadharan; Adnan Majid; Olivier N Kocher; Michael A Goldstein; Mark S Huberman; Daniel B Costa Journal: Lung Cancer Date: 2013-08-07 Impact factor: 5.705
Authors: Haiying Cheng; H Dean Hosgood; Lei Deng; Kenny Ye; Christopher Su; Janaki Sharma; Yuanquan Yang; Balazs Halmos; Roman Perez-Soler Journal: Clin Lung Cancer Date: 2019-07-17 Impact factor: 4.785
Authors: Christine M Lusk; Donovan Watza; Greg Dyson; Douglas Craig; Valerie Ratliff; Angela S Wenzlaff; Fulvio Lonardo; Aliccia Bollig-Fischer; Gerold Bepler; Kristen Purrington; Shirish Gadgeel; Ann G Schwartz Journal: Clin Cancer Res Date: 2019-04-12 Impact factor: 12.531
Authors: Nicholas T Gimbrone; Bhaswati Sarcar; Edna R Gordian; Jason I Rivera; Christian Lopez; Sean J Yoder; Jamie K Teer; Eric A Welsh; Alberto A Chiappori; Matthew B Schabath; Gary W Reuther; Julie Dutil; Miosotis Garcia; Ronald Ventosilla-Villanueva; Luis Vera-Valdivia; Alejandro Yabar-Berrocal; Rodrigo Motta-Guerrero; Pedro G Santiago-Cardona; Teresita Muñoz-Antonia; W Douglas Cress Journal: J Thorac Oncol Date: 2017-09-11 Impact factor: 15.609
Authors: Elisabeth I Heath; Filipa Lynce; Joanne Xiu; Angela Ellerbrock; Sandeep K Reddy; Elias Obeid; Stephen V Liu; Aliccia Bollig-Fischer; Duska Separovic; Ari Vanderwalde Journal: Anticancer Res Date: 2018-04 Impact factor: 2.480